Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
revised:
25
06
2021
received:
07
04
2021
accepted:
22
07
2021
pubmed:
27
7
2021
medline:
28
9
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
Chimeric antigen receptor (CAR)-T cell therapies have improved the outcome for many patients with relapsed or refractory aggressive B-cell lymphomas. In 2017, axicabtagene ciloleucel and soon after tisagenlecleucel became the first approved CAR-T cell products for patients with high-grade B-cell lymphomas or diffuse large B-cell lymphoma (DLBCL) who are relapsed or refractory to ≥ 2 prior lines of therapy; lisocabtagene maraleucel was approved in 2021. Safety and efficacy outcomes from the pivotal trials of each CAR-T cell therapy have been reported. Despite addressing a common unmet need in the large B-cell lymphoma population and utilizing similar CAR technologies, there are differences between CAR-T cell products in manufacturing, pivotal clinical trial designs, and data reporting. Early reports of commercial use of axicabtagene ciloleucel and tisagenlecleucel provide the first opportunities to validate the impact of patient characteristics on the efficacy and safety of these CAR-T cell therapies in the real world. Going forward, caring for patients after CAR-T cell therapy will require strategies to monitor patients for sustained responses and potential long-term side effects. In this review, product attributes, protocol designs, and clinical outcomes of the key clinical trials are presented. We discuss recent data on patient characteristics, efficacy, and safety of patients treated with axicabtagene ciloleucel or tisagenlecleucel in the real world. Finally, we discuss postinfusion management and preview upcoming clinical trials of CAR-T cell therapies.
Identifiants
pubmed: 34310745
doi: 10.1002/ajh.26301
pmc: PMC9290945
doi:
Substances chimiques
Antigens, CD19
0
Biological Products
0
Receptors, Antigen, T-Cell
0
tisagenlecleucel
Q6C9WHR03O
axicabtagene ciloleucel
U2I8T43Y7R
Banques de données
ClinicalTrials.gov
['NCT02445248', 'NCT02348216', 'NCT02631044']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1295-1312Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.
Références
Blood Adv. 2020 Apr 14;4(7):1440-1447
pubmed: 32271898
Blood. 2021 May 13;137(19):2621-2633
pubmed: 33512407
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Transplant Cell Ther. 2022 Jul 15;:
pubmed: 35850429
Lancet Oncol. 2019 Jan;20(1):2-3
pubmed: 30518503
JAMA Oncol. 2018 Jul 1;4(7):994-996
pubmed: 29710129
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
Am J Hematol. 2021 Oct 1;96(10):1295-1312
pubmed: 34310745
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
Leukemia. 2021 Dec;35(12):3581-3584
pubmed: 34145373
Blood Adv. 2020 Nov 10;4(21):5414-5424
pubmed: 33147337
J Clin Oncol. 2019 Aug 20;37(24):2105-2119
pubmed: 31157579
N Engl J Med. 2021 Feb 18;384(7):673-674
pubmed: 33596362
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
J Immunother. 2009 Sep;32(7):689-702
pubmed: 19561539
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Haematologica. 2021 Apr 01;106(4):978-986
pubmed: 32327504
Mol Cancer. 2019 Aug 20;18(1):125
pubmed: 31429760
N Engl J Med. 2011 Aug 25;365(8):725-33
pubmed: 21830940
Drug Saf. 2019 Feb;42(2):295-314
pubmed: 30649747
Immunity. 2016 Mar 15;44(3):712
pubmed: 28843072
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Mol Ther. 2009 Aug;17(8):1453-64
pubmed: 19384291
Mol Ther. 2017 Jan 4;25(1):285-295
pubmed: 28129122
J Clin Oncol. 2020 Sep 20;38(27):3119-3128
pubmed: 32401634
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Blood Adv. 2020 Oct 13;4(19):4898-4911
pubmed: 33035333
Mol Ther Methods Clin Dev. 2019 Nov 29;16:136-144
pubmed: 31988978
Blood. 2017 Nov 23;130(21):2317-2325
pubmed: 28935694
JAMA Netw Open. 2020 Apr 1;3(4):e202072
pubmed: 32250433
Am J Hematol. 2020 Nov;95(11):1324-1333
pubmed: 32744738
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
JAMA Netw Open. 2019 Feb 1;2(2):e190035
pubmed: 30794298
Cytotherapy. 2019 Dec;21(12):1198-1205
pubmed: 31837735
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
Oncologist. 2006 Feb;11(2):90-5
pubmed: 16476830
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Blood Adv. 2020 Apr 14;4(7):1432-1439
pubmed: 32271899
J Clin Oncol. 2020 Sep 20;38(27):3095-3106
pubmed: 32667831
J Hematol Oncol. 2021 Apr 19;14(1):65
pubmed: 33874996
Blood Adv. 2020 Jul 14;4(13):2871-2883
pubmed: 32589728
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797